Sulzer Shareholders Must Weigh Value Of Non-Medical Businesses
This article was originally published in The Gray Sheet
Executive Summary
Sulzer Ltd. will have to convince its shareholders before the firm's April 19 annual meeting that a share in the non-medical portion of its business has a greater value than the $241-per-share cash component of investor group InCentive Capital's unsolicited bid for the company.
You may also be interested in...
Sulzer Medica
Spin-off of medical device unit from parent Sulzer Ltd. is slated for July 10 following shareholder meeting on July 9. Following spin-off, the parent will retain a 4% stake in firm. Sulzer management first announced its spinout plan March 9 on the heels of a hostile takeover bid from investor group InCentive Capital. The bid has since failed (1"The Gray Sheet" March 12, 2001, p. 27). Firm also announces appointment of Stephen Rietiker as CEO of the Medica unit, effective August 1. Rietiker, formerly VP and general manager of Covance, replaces current CEO Andre Buchel, who will retire
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.